Vildagliptin: a review of its use in the management of type 2 diabetes mellitus.

Abstract:

:Vildagliptin (Galvus) is an antihyperglycaemic agent that selectively inhibits the dipeptidyl peptidase-4 (DPP-4) enzyme. Such inhibition prevents the degradation of the incretin hormones glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). This results in improved glycaemic control as determined by glycated haemoglobin (HbA(1c)) and fasting plasma glucose (FPG) levels, and, in addition, an enhancement of pancreatic alpha- and beta-cell function. Vildagliptin is indicated in the EU and elsewhere in the world for the management of type 2 diabetes mellitus in combination with metformin, a sulfonylurea or a thiazolidinedione in patients with inadequate glycaemic control following monotherapy. Vildagliptin is also available as a fixed-dose formulation with metformin (Eucreas).Oral vildagliptin in combination with metformin, a sulfonylurea or a thiazolidinedione improved glycaemic control in adults with type 2 diabetes and appeared to slow the progression of beta-cell degeneration in trials of 24-52 weeks' duration. In trials in patients with diabetes inadequately controlled with metformin, vildagliptin provided an additional reduction of HbA(1c) levels of 1.1% and was shown to be as effective as pioglitazone as add-on therapy in a noninferiority trial. Vildagliptin had a low risk of hypoglycaemia, was weight-neutral overall and was generally well tolerated. Further investigation is required to accurately position vildagliptin relative to other, well established antidiabetic agents. However, the addition of vildagliptin expands the range of treatment options available, and as such, offers further potential for the management of patients with type 2 diabetes that is inadequately controlled with monotherapy.

journal_name

Drugs

journal_title

Drugs

authors

Croxtall JD,Keam SJ

doi

10.2165/0003495-200868160-00009

subject

Has Abstract

pub_date

2008-01-01 00:00:00

pages

2387-409

issue

16

eissn

0012-6667

issn

1179-1950

pii

68169

journal_volume

68

pub_type

杂志文章,评审

相关文献

DRUGS文献大全
  • Antirheumatic drugs: clinical pharmacological and therapeutic aspects.

    abstract::There are many current concepts of the pathogenesis of rheumatic diseases which incorporate immunological, infectious and hereditary factors. Rheumatic diseases may sometimes become apparent after trauma, be associated with certain diseases and may be induced by nerve damage and serum sickness. Systemic lupuserythemat...

    journal_title:Drugs

    pub_type: 杂志文章

    doi:10.2165/00003495-197510050-00008

    authors: Smyth CJ,Bravo JF

    更新日期:1975-01-01 00:00:00

  • Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomis

    abstract:BACKGROUND:The lowering of cholesterol concentrations in individuals at high risk of cardiovascular disease improves outcome. No study, however, has assessed benefits of cholesterol lowering in the primary prevention of coronary heart disease (CHD) in hypertensive patients who are not conventionally deemed dyslipidaemi...

    journal_title:Drugs

    pub_type: 临床试验,杂志文章,多中心研究,随机对照试验

    doi:10.2165/00003495-200464002-00005

    authors: Sever PS,Dahlöf B,Poulter NR,Wedel H,Beevers G,Caulfield M,Collins R,Kjeldsen SE,Kristinsson A,McInnes GT,Mehlsen J,Nieminen M,O'Brien E,Ostergren J,ASCOT Investigators.

    更新日期:2004-01-01 00:00:00

  • Insulin degludec and insulin degludec/insulin aspart: a review of their use in the management of diabetes mellitus.

    abstract::Insulin degludec (Tresiba(®)) is an ultra-long-acting insulin analogue that is also available as a coformulation with rapid-acting insulin aspart (insulin degludec/insulin aspart) [Ryzodeg(®)]. Insulin degludec has a flat, stable glucose-lowering profile with a duration of action of >42 h, and less within-patient day-...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-013-0051-1

    authors: Keating GM

    更新日期:2013-05-01 00:00:00

  • Desirable therapeutic characteristics of an optimal antihypertensive agent.

    abstract::Hypertension affects 65 million people in the US, and is a major cause of morbidity and mortality, but less than one-third of patients with hypertension are treated to goal blood pressure. Multiple factors have been cited, and include suboptimal adherence to treatment and lifestyle modifications, limited access to hea...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200666090-00006

    authors: Mustone Alexander L

    更新日期:2006-01-01 00:00:00

  • Current Treatments and New Developments in the Management of Glucocorticoid-induced Osteoporosis.

    abstract::Glucocorticoids (GCs) are often used for improvement of quality of life, particularly in the elderly, but long-term GC use may cause harm; bone loss and fractures are among the most devastating side effects. Fracture risk is particularly high in patients with a severe underlying disease with an urgent need for treatme...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-019-01145-6

    authors: Raterman HG,Bultink IEM,Lems WF

    更新日期:2019-07-01 00:00:00

  • Tranexamic acid: a review of its use in surgery and other indications.

    abstract:UNLABELLED:Tranexamic acid is a synthetic derivative of the amino acid lysine that exerts its antifibrinolytic effect through the reversible blockade of lysine binding sites on plasminogen molecules. Intravenously administered tranexamic acid (most commonly 10 mg/kg followed by infusion of 1 mg/kg/hour) caused reductio...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199957060-00017

    authors: Dunn CJ,Goa KL

    更新日期:1999-06-01 00:00:00

  • A Retrospective Cohort Study of Obstetric Outcomes in Opioid-Dependent Women Treated with Implant Naltrexone, Oral Methadone or Sublingual Buprenorphine, and Non-Dependent Controls.

    abstract:BACKGROUND:Opioid pharmacotherapies play an important role in the treatment of opioid-dependent women; however, very little is known about the safety of naltrexone in pregnant patients. OBJECTIVE:This study examined the obstetric health of opioid-dependent women who were treated with implant naltrexone during pregnanc...

    journal_title:Drugs

    pub_type: 杂志文章,meta分析

    doi:10.1007/s40265-017-0762-9

    authors: Kelty E,Hulse G

    更新日期:2017-07-01 00:00:00

  • Enoxaparin. A review of its clinical potential in the management of coronary artery disease.

    abstract:UNLABELLED:Enoxaparin (enoxaparin sodium) is a low molecular weight heparin (LMWH) that is widely used in the prevention of deep venous thrombosis and pulmonary embolism in patients undergoing orthopaedic or general surgery. Its efficacy in these indications has led to study of its use in patients with coronary artery ...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199856020-00013

    authors: Noble S,Spencer CM

    更新日期:1998-08-01 00:00:00

  • Diuretics. Clinical pharmacology and therapeutic use (Part II).

    abstract::25 years have elapsed since the introduction of the first effective oral diuretic, chlorothiazide. Diuretics are now amongst the most widely prescribed drugs in clinical practice worldwide. Availability of these drugs has not only brought therapeutic benefit to countless numbers of patients but it has at the same time...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-198529020-00003

    authors: Lant A

    更新日期:1985-02-01 00:00:00

  • ZD1839 ('Iressa') as an anticancer agent.

    abstract::ZD1839 ('Iressa') is an orally active, selective epidermal growth factor receptor-tyrosine kinase inhibitor which blocks signal transduction pathways implicated in the proliferation and survival of cancer cells and other host-dependent processes promoting cancer growth. In preclinical studies, ZD1839 produced reversib...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200060001-00004

    authors: Baselga J,Averbuch SD

    更新日期:2000-01-01 00:00:00

  • Panobinostat: first global approval.

    abstract::Novartis has developed oral and intravenous formulations of panobinostat (Farydak(®)), a histone deacetylase (HDAC) inhibitor, for the treatment of cancer. HDACs have important roles in maintaining chromatin structure and in regulating gene expression, including that of tumour suppressor genes, and thus represent vali...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-015-0388-8

    authors: Garnock-Jones KP

    更新日期:2015-04-01 00:00:00

  • Sirolimus use in recipients of expanded criteria donor kidneys.

    abstract::With changing donor characteristics and the growing shortage in organ supply, renal transplant practitioners have sought to optimize the use of expanded criteria donor (ECD) kidneys, which have poorer outcomes than standard criteria donor (SCD) kidneys. The outcomes may represent an acceptable trade-off if ECD transpl...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200868001-00006

    authors: House AA,Nguan CY,Luke PP

    更新日期:2008-01-01 00:00:00

  • The role of proton pump inhibitors in gastro-oesophageal reflux disease.

    abstract::The proton pump inhibitors (PPIs) are the most successful class of drugs that have been introduced for the treatment of gastro-oesophageal reflux disease (GORD) because of their profound and consistent effect on gastric acid secretion. The PPIs have demonstrated an excellent adverse effect profile after approximately ...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200464030-00004

    authors: Dekel R,Morse C,Fass R

    更新日期:2004-01-01 00:00:00

  • Dual inhibitory action of nedocromil sodium on antigen-induced inflammation.

    abstract::In human lung tissue in vitro, nedocromil sodium inhibited the release of histamine and leukotrienes induced by anti-IgE, as well as the contraction of isolated bronchi which followed this challenge. In the hamster cheek pouch in vivo, nedocromil sodium inhibited the inflammatory response induced by challenge with eit...

    journal_title:Drugs

    pub_type: 杂志文章

    doi:10.2165/00003495-198900371-00013

    authors: Dahlén SE,Björck T,Kumlin M,Sydbom A,Raud J,Palmertz U,Franzén L,Grönneberg R,Hedqvist P

    更新日期:1989-01-01 00:00:00

  • Balanced analgesia: what is it and what are its advantages in postoperative pain?

    abstract::The concept of balanced analgesia was introduced to improve analgesic efficacy and reduce adverse effects. A large amount of clinical data has documented improved analgesia by combining different analgesics, but data on reducing adverse effects are inconclusive. Balanced analgesia should be used whenever possible, and...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199958050-00002

    authors: Kehlet H,Werner M,Perkins F

    更新日期:1999-11-01 00:00:00

  • Management of chronic obstructive pulmonary disease.

    abstract::Chronic obstructive pulmonary disease (COPD) is characterised by insidiously progressive airflow limitation. The necessarily multifactorial management programme should include smoking cessation, prevention of infections, bronchodilator and steroid therapy, supplemental oxygen, physical therapy, pulmonary rehabilitatio...

    journal_title:Drugs

    pub_type: 临床试验,杂志文章,评审

    doi:10.2165/00003495-198938010-00007

    authors: Kesten S,Rebuck AS

    更新日期:1989-07-01 00:00:00

  • Aliskiren/hydrochlorothiazide combination: in mild to moderate hypertension.

    abstract::Aliskiren/hydrochlorothiazide is a single-pill combination of the first in the new class of non-peptide direct renin inhibitors (aliskiren) and a thiazide diuretic (hydrochlorothiazide [HCTZ]) that achieves blood pressure (BP) reductions greater than those seen with either component alone. In double-blind, 8-week clin...

    journal_title:Drugs

    pub_type: 杂志文章

    doi:10.2165/00003495-200969070-00004

    authors: Baldwin CM,Plosker GL

    更新日期:2009-01-01 00:00:00

  • Combination antiretroviral therapy. Back to the future.

    abstract::HIV causes chronic infection and is associated with persistent viral replication and a high viral mutation rate. It is an illusion to think that monotherapy with any antiretroviral agent will have a major and lasting impact on this disease. Monotherapy with antitubercular agents led to dramatic improvements in treatme...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199500491-00008

    authors: Lange J

    更新日期:1995-01-01 00:00:00

  • Effects of enalapril on clinical status, biochemistry, exercise performance and haemodynamics in heart failure.

    abstract::The effects of enalapril on clinical well-being, treadmill exercise performance, haemodynamic measurements, hormone levels, and plasma biochemistry in patients with moderate heart failure, were assessed in a 12-week placebo-controlled, double-blind study. Maintenance frusemide and digoxin treatment was continued throu...

    journal_title:Drugs

    pub_type: 临床试验,杂志文章

    doi:10.2165/00003495-198500301-00011

    authors: Webster MW,Fitzpatrick MA,Hamilton EJ,Nicholls MG,Ikram H,Espiner EA,Wells JE

    更新日期:1985-01-01 00:00:00

  • Management of cytomegalovirus infection after solid-organ or stem-cell transplantation. Current guidelines and future prospects.

    abstract::Recent developments in diagnosis and therapy of cytomegalovirus (CMV) infection have helped to reduce CMV-associated mortality following organ transplantation. However, CMV is still associated with significant morbidity in recipients of an allogeneic stem cell or solid-organ transplant. The clinical symptoms of active...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199855010-00005

    authors: Hebart H,Kanz L,Jahn G,Einsele H

    更新日期:1998-01-01 00:00:00

  • Inhaled Umeclidinium in COPD Patients: A Review and Meta-Analysis.

    abstract::A number of new agents for the management of chronic obstructive pulmonary disease (COPD) are at different stages of development, including several inhaled long-acting antimuscarinics (LAMA). Long-acting bronchodilators are considered to be central to the management of COPD due to the evidence supporting their efficac...

    journal_title:Drugs

    pub_type: 杂志文章,meta分析,评审

    doi:10.1007/s40265-015-0532-5

    authors: Pleasants RA,Wang T,Gao J,Tang H,Donohue JF

    更新日期:2016-03-01 00:00:00

  • Japanese encephalitis vaccine (inactivated, adsorbed) [IXIARO].

    abstract::The Japanese encephalitis vaccine IC-51 (IXIARO) is an inactivated virus (strain SA(14)-14-2) that is manufactured in cultured Vero cells and is currently being developed for preventive vaccination against the Japanese encephalitis virus. black triangle Administration of IXIARO as a two-dose treatment in healthy adult...

    journal_title:Drugs

    pub_type: 杂志文章

    doi:10.2165/00003495-200969010-00008

    authors: Duggan ST,Plosker GL

    更新日期:2009-01-01 00:00:00

  • Supra-oesophageal manifestations of gastro-oesophageal reflux disease.

    abstract::The extra-oesophageal signs that are most commonly related to gastro-oesophageal reflux include chest pain, asthma, chronic cough, posterior laryngitis and dental erosions. It is characteristic to find in such patients a poor presence of symptoms and endoscopic and pH-metric findings that are common in typical reflux....

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200565001-00010

    authors: Rodríguez-Téllez M

    更新日期:2005-01-01 00:00:00

  • Flecainide. A preliminary review of its pharmacodynamic properties and therapeutic efficacy.

    abstract::Flecainide is a Class I antiarrhythmic drug of the local anaesthetic type. It can be given either intravenously or orally and its pharmacokinetic properties allow relatively long (12 hours) dosing intervals with oral administration. In several open and a few controlled therapeutic trials, orally administered flecainid...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-198529010-00001

    authors: Holmes B,Heel RC

    更新日期:1985-01-01 00:00:00

  • Olaratumab: First Global Approval.

    abstract::Olaratumab (Lartruvo™) is a fully human IgG1 monoclonal antibody targeted against the human platelet-derived growth factor (PDGF) receptor α (PDGFRα). It was developed by Eli Lilly and Co. (previously ImClone Systems) after PDGFRα was identified as a potential therapeutic target in a variety of cancers. Olaratumab act...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-016-0680-2

    authors: Shirley M

    更新日期:2017-01-01 00:00:00

  • Sickle cell disease in children.

    abstract::Early identification of infants with sickle cell disease (SCD) by newborn screening, now universal in all 50 states in the US, has improved survival, mainly by preventing overwhelming sepsis with the early use of prophylactic penicillin. Routine transcranial Doppler screening with the institution of chronic transfusio...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/11632890-000000000-00000

    authors: Meier ER,Miller JL

    更新日期:2012-05-07 00:00:00

  • Therapeutic experience with temocillin in peritonitis.

    abstract::The therapeutic efficacy of the new beta-lactam antibiotic, temocillin, was studied in 30 critically ill patients with peritonitis, abscesses, bronchopneumonia, and serious soft tissue infections. Patients were treated with temocillin Ig intravenously twice daily. The isolated pathogens comprised mainly Escherichia co...

    journal_title:Drugs

    pub_type: 杂志文章

    doi:10.2165/00003495-198500295-00042

    authors: Pfeiffer M,Fock RR

    更新日期:1985-01-01 00:00:00

  • Antibiotics in neonatal infections: a review.

    abstract::The bacteria most commonly responsible for early-onset (materno-fetal) infections in neonates are group B streptococci, enterococci, Enterobacteriaceae and Listeria monocytogenes. Coagulase-negative staphylococci, particularly Staphylococcus epidermidis, are the main pathogens in late-onset (nosocomial) infections, es...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199958030-00003

    authors: Fanos V,Dall'Agnola A

    更新日期:1999-09-01 00:00:00

  • Epidemiological considerations in the treatment of hypertension.

    abstract::Cardiovascular disease continues to be the principal cause of death in Western countries. Epidemiological studies have repeatedly demonstrated a striking relationship between blood pressure and the risk of cardiovascular disease in that those with the highest levels of blood pressure are at the greatest risk for subse...

    journal_title:Drugs

    pub_type: 杂志文章

    doi:10.2165/00003495-198600314-00003

    authors: Whelton PK,Klag MJ

    更新日期:1986-01-01 00:00:00

  • New and Emerging Therapies for Alopecia Areata.

    abstract::Alopecia areata (AA) is an autoimmune condition that affects up to 2% of the general population. Currently available treatment options for AA are of limited efficacy and can be associated with adverse effects. The advancement in understanding of the genetic and molecular mechanisms of AA has led to the development of ...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-020-01293-0

    authors: Pourang A,Mesinkovska NA

    更新日期:2020-05-01 00:00:00